Concurrent Weekly Docetaxel Chemotherapy in Combination with Radiotherapy for Stage III and IVA-B Nasopharyngeal Carcinoma

Wei, Wei-Hong; Cai, Xiu-Yu; Xu, Tao; Zhang, Guo-Yi; Wu, Yong-Feng; Feng, Wei-Neng; Lin, Li; Deng, Yan-Ming; Lu, Qiu-Xia; Huang, Zhe-Li

추천

검색

자료유형: 학술저널

저자정보: Wei, Wei-Hong (Department of Radiation Oncology, First People's Hospital of Foshan Affiliated to Sun Yat-sen University) Cai, Xiu-Yu (Department of Medical Oncology, State Key Laboratory of Oncology in South China, Cancer Center, Sun Yat-Sen University) Xu, Tao (Department of Radiation Oncology, First People's Hospital of Foshan Affiliated to Sun Yat-sen University) Zhang, Guo-Yi (Department of Radiation Oncology, First People's Hospital of Foshan Affiliated to Sun Yat-sen University) Wu, Yong-Feng (Department of Radiation Oncology, First People's Hospital of Foshan Affiliated to Sun Yat-sen University) Feng, Wei-Neng (Department of Medical Oncology, First People's Hospital of Foshan Affiliated to Sun Yat-sen University) Lin, Li (Department of Radiation Oncology, First People's Hospital of Foshan Affiliated to Sun Yat-sen University) Deng, Yan-Ming (Department of Medical Oncology, First People's Hospital of Foshan Affiliated to Sun Yat-sen University) Lu, Qiu-Xia (Department of Radiation Oncology, First People's Hospital of Foshan Affiliated to Sun Yat-sen University) Huang, Zhe-Li (Department of Radiation Onc)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제13권 제3호

발행연도: 2012.1

수록면: 785 - 789 (5page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Background and Purpose: Cisplatin is the most common chemotherapeutic agent for loco-regionally advanced nasopharyngeal carcinoma (NPC); however, toxicity is a limiting factor for some patients. We retrospectively compared the efficacy and toxicity of weekly docetaxel-based and cisplatin-based concurrent chemoradiotherapy in loco-regionally advanced NPC. Methods and Materials: Eighty-four patients with Stage III and IVA-B NPCs, treated between 2007 and 2008, were retrospectively analyzed. Thirty received weekly docetaxel-based concurrent chemotherapy, and 43 were given weekly cisplatin-based concurrent chemotherapy. Radiotherapy was administered using a conventional technique (seven weeks, 2.0 Gy per fraction, total dose 70-74 Gy) with 6-8 Gy boosts for some patients with locally advanced disease. Results: Median follow-up time was 42.3 months (range, 8.6-50.8 months). There were no significant differences in the 3-year loco-regional failure-free survival (85.6% vs. 92.3%; p=0.264), distant failure-free survival (87.0% vs. 92.5%; p=0.171), progression-free survival (85.7% vs. 88.4%; p=0.411) or overall survival (86.5% vs. 92.5%, p=0.298) of patients treated concurrently with docetaxel or cisplatin. Severe toxicity was not common in either group. Conclusions: Weekly docetaxel-based concurrent chemoradiotherapy is potentially effective and has a tolerable toxicity; however, further investigations are required to determine if docetaxel is superior to cisplatin for advanced stage NPC.

#Cisplatin #chemoradiotherapy #nasopharyngeal carcinoma #docetaxel

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요

이 논문의 저자 정보

Wei, Wei-Hong

소속기관 Department of Radiation Oncology, First People's Hospital of Foshan Affiliated to Sun Yat-sen Univer